Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02611323
Title A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Hoffmann-La Roche

diffuse large B-cell lymphoma

follicular lymphoma

B-cell lymphoma

non-Hodgkin lymphoma


Polatuzumab vedotin-piiq + Rituximab + Venetoclax

Obinutuzumab + Polatuzumab vedotin-piiq + Venetoclax

Age Groups: senior | adult
Covered Countries USA | ITA

No variant requirements are available.